TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04357327

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rapid salivary test
Description: a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rapid salivary test
Description: a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
Study: NCT03902054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of low dosage investigational sIPV
Description: The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized sIPV
Description: The control vaccine was manufactured by Chinese Academy of Medical Sciences.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized IPV
Description: The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
Study: NCT02099474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy
Description: Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
Study: NCT03763708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming
Study: NCT04013256

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air and Clean Clothing/Sham exposure
Description: Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing.
Study: NCT02159859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
Study: NCT04255459

Intervention type: OTHER
Group type: OTHER
Intervention: Moist Snuff
Description: Moist Snuff product

Intervention type: OTHER
Group type: OTHER
Intervention: Moist Snuff
Description: Moist Snuff product

Intervention type: OTHER
Group type: OTHER
Intervention: Camel Snus
Description: Camel Snus product

Intervention type: OTHER
Group type: OTHER
Intervention: Camel Snus
Description: Camel Snus product

Intervention type: OTHER
Group type: OTHER
Intervention: Cigarettes
Description: Cigarette product

Intervention type: OTHER
Group type: OTHER
Intervention: Cigarettes
Description: Cigarette product

Intervention type: OTHER
Group type: OTHER
Intervention: Cigarettes
Description: Cigarette product

Intervention type: OTHER
Group type: OTHER
Intervention: No tobacco usage
Description: No tobacco usage
Study: NCT04882111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIGN
Description: The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
Study: NCT01271114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline and Terlipressin
Description: Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline and norepinephrine
Description: Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
Study: NCT01861327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO2
Description: carbon dioxide (CO2) as arterial contrast media

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO2
Description: carbon dioxide (CO2) as arterial contrast media

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO2
Description: carbon dioxide (CO2) as arterial contrast media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine contrast media
Description: Iodine as arterial contrast media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine contrast media
Description: Iodine as arterial contrast media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine contrast media
Description: Iodine as arterial contrast media
Study: NCT03346395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving based intervention
Description: Problem solving based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
Study: NCT03491878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three dimensional laparoscopic
Description: Three dimensional laparoscopic cholecystectomy including segments IVB and V

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open
Description: Open cholecystectomy including segments IVB and V
Study: NCT00631111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: effervescent ibuprofen tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: effervescent Aspirin plus Vitamin C tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01396044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic checklist
Description: Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal prompting
Description: Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
Study: NCT02429700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
Study: NCT03947216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active drug: pimavanserin 17mg (2 strength tablets)
Description: Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
Study: NCT02429700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT03967132

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ready to feed infant formula, feed ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ready to feed infant formula, feed ad libitum

Intervention type: OTHER
Group type: OTHER
Intervention: Reference Group
Description: Human milk, breast feeding ad libitum
Study: NCT00826397

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
Study: NCT03900169

Intervention type: GENETIC
Intervention: Genetic
Description: Lipid profile
Study: NCT03417557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A lens (test)
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon B lens (control)
Description: contact lens
Study: NCT04088175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Virginia Tobacco 5% nicotine strength
Description: JUUL ENDS - Virginia Tobacco 5% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Virginia Tobacco 3% nicotine strength
Description: JUUL ENDS - Virginia Tobacco 3% nicotine strength
Study: NCT04149587

Intervention type: DRUG
Intervention: Brodalumab
Description: Brodalumab will be administered per dose and schedule specified in the arm.
Study: NCT03953209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 50Mg Tablet
Description: Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
Study: NCT04088175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Menthol 5% nicotine strength
Description: JUUL ENDS - Menthol 5% nicotine strength
Study: NCT02010723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sclerotherapy with aethoxysclerol foam
Description: foam sclerotherapy with aethoxysclerol foam
Study: NCT02042911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
Study: NCT01666886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Study: NCT02639208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PatientsLikeMe (PLM)
Study: NCT00673790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol with concomitant losartan or lisinopril
Description: Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ with concomitant losartan or lisinopril
Description: Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with concomitant losartan or lisinopril
Description: Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
Study: NCT04244747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: induction of labor by breast stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: induction of labor by catheter balloon
Study: NCT04088175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Menthol 3% nicotine strength
Description: JUUL ENDS - Menthol 3% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mint 5% nicotine strength
Description: JUUL ENDS - Mint 5% nicotine strength
Study: NCT03366285

Intervention type: DIAGNOSTIC_TEST
Intervention: Attachment story completion taks (ASCT)
Description: Bonding quality
Study: NCT04088175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mint 3% nicotine strength
Description: JUUL ENDS - Mint 3% nicotine strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mango 5% nicotine strength
Description: JUUL ENDS - Mango 5% nicotine strength
Study: NCT03366285

Intervention type: DIAGNOSTIC_TEST
Intervention: Attachment story completion taks (ASCT)
Description: Bonding quality

Intervention type: DIAGNOSTIC_TEST
Intervention: Attachment story completion taks (ASCT)
Description: Bonding quality

Intervention type: DIAGNOSTIC_TEST
Intervention: Attachment story completion taks (ASCT)
Description: Bonding quality
Study: NCT03953209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 100Mg Tablet
Description: Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 200Mg
Description: Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
Study: NCT01368055

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 70 Gy/CGE
Description: Low Risk
Study: NCT04088175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mango 3% nicotine strength
Description: JUUL ENDS - Mango 3% nicotine strength
Study: NCT01387100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Rehabilitation Intervention
Description: Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
Study: NCT02976740

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunological Agent
Description: Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunological Factors
Description: Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
Study: NCT04989062

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Controlled attenuation parameter and liver stiffness measurement are measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analysis
Description: Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
Study: NCT01368055

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 72.5 Gy/CGE
Description: Intermediate Risk
Study: NCT04989062

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine unclear magnetic resonance metabolomics
Description: Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand grip strength
Description: Hand grip strength in both hands is measured by hand-held dynamometer.
Study: NCT00892697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
Study: NCT03947216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 2 tablets containing same excipients except active compound
Description: Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of severity of ICD (impulse control disorders)
Description: Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of severity of ICD (impulse control disorders)
Description: Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Description: Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Description: Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study: NCT00892697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
Study: NCT02168647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Lifestyle counseling
Description: Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.